Study With Trabectedin in BRCA1 and BRCA2 Mutation Carrier and BRCAness Phenotype Ovarian Cancer
Status:
Unknown status
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
This is a multicenter phase II study on trabectedin in advanced or recurrent ovarian cancer
patients with BRCA mutation and BRCAness phenotype.
The purpose of this study is to determine the feasibility in terms of objective response rate
by RECIST version 1.1 (Complete and Partial Response [CR + PR]) with trabectedin in patients
with BRCA1 or BRCA2 mutation carrier or BRCAness phenotype advanced ovarian cancer patients.